Background: Increased mortality in schizophrenia is caused largely by CHD. Low cardiorespiratory fitness (CRF) is a key factor for CHD mortality. We compared CRF in patients with schizophrenia to CRF of matched healthy controls and reference values. Also, we examined the effects of exercise therapy on CRF in patients with schizophrenia and in controls. Methods: Sixty-three patients with schizophrenia and 55 controls, matched for gender, age, and socioeconomic status, were randomized to exercise (n = 31) or occupational therapy (n = 32) and controls to exercise (n = 27) or life as usual (n = 28). CRF was assessed with an incremental cardiopulmonary exercise test and defined as the highest relative oxygen uptake (V O 2peak ) and peak work rate (W peak ). Minimal compliance was 50% of sessions (n = 52). Results: Male and female patients with schizophrenia had a relative V O 2peak of 34.3 T 9.9 and 24.0 T 4.5 mLIkg j1 Imin j1 , respectively. Patients had higher resting HR (P G 0.01) and lower peak HR (P G 0.001), peak systolic blood pressure (P = 0.02), relative V O 2peak (P G 0.01), W peak (P G 0.001), RER (P G 0.001), minute ventilation (P = 0.02), and HR recovery (P G 0.001) than controls. Relative V O 2peak was 90.5% T 19.7% (P G 0.01) of predicted relative V O 2peak in male and 95.9% T 14.9% (P = 0.18) in female patients. In patients, exercise therapy increased relative V O 2peak compared with decreased relative V O 2peak after occupational therapy. In controls, relative V O 2peak increased after exercise therapy and to a lesser extent after life as usual (group, P G 0.01; randomization, P = 0.03). Exercise therapy increased W peak in patients and controls compared with decreased W peak in nonexercising patients and controls (P G 0.001). Conclusion: Patients had lower CRF levels compared with controls and reference values. Exercise therapy increased V O 2peak and W peak in patients and controls. V O 2peak and W peak decreased in nonexercising patients.
S chizophrenia is a severe and chronic psychiatric illness characterized by a marked decline in functioning. Even after treatment with antipsychotic medication, patients with schizophrenia typically are at high risk for relapse and manifest multiple somatic comorbidities (20) . Patients with schizophrenia have a two-to threefold increased mortality rate compared with the general population (41), resulting in a 20% reduction in life expectancy (36) . Up to 40% of excess mortality can be attributed to suicide and unnatural deaths (12) . In schizophrenia, standardized mortality ratios of most major natural death categories are increased compared with the general population (i.e., digestive, endocrine, infectious, and nervous diseases) (36) . The single largest cause of death in patients with schizophrenia is CHD. Patients with schizophrenia are two times more likely to die of CHD than the general population (11) .
Several lifestyle factors influence the physical health status of patients with schizophrenia and negatively affect their risk for CHD. Patients with schizophrenia are much more likely to smoke, and 70% to 75% of patients with schizophrenia can be classified as being physically inactive and do not meet minimal physical activity recommendations (15, 30) . In addition, patients with schizophrenia are more likely to have a reduced nutritional status because of an unhealthy diet (31) . Moreover, many atypical antipsychotics induce significant weight gain, increasing the risk of diabetes mellitus Type II, the metabolic syndrome, and ultimately CHD (33, 35) .
Besides the abovementioned factors, low cardiorespiratory fitness (CRF) has been recognized as an independent risk factor for all-cause mortality in adults and a key risk factor for CHD-related mortality (5, 26) . A recent meta-analysis in the healthy population has shown an inverse association between CRF and CHD. In men, low CRF was found to predict mortality due to CHD even better than smoking, hypertension, or diabetes (26) . In schizophrenia, high-quality studies investigating CRF are scarce (42) . A cross-sectional study reported obese patients with schizophrenia had low CRF levels compared with population standards. Strikingly, only two participants in the entire sample (n = 117) fit the categorization of ''moderate fitness level.'' All other participants scored below population standards. This indicates poor CRF is a key modifiable risk factor (37) . Interestingly, a recent trial showed that 8 wk of high-intensity, anaerobic exercise training increased CRF in patients with schizophrenia (22) . A large Finnish cohort sample showed adolescents who later developed psychosis, at the age of 15-16 yr, had a relatively low level of CRF (odds ratio, 2.2; 95% confidence interval, 0.6-7.8), as measured using a submaximal cycle ergometer test (27) .
To the best of our knowledge, no prior randomized controlled trial has examined the effects of an exercise intervention on CRF in patients with schizophrenia and matched healthy controls. Thus, we studied whether CRF in patients with schizophrenia is lower compared with matched physically inactive but otherwise healthy controls as well as compared with reference values. Furthermore, we investigated whether a 6-month exercise program improves CRF in patients with schizophrenia and controls.
METHODS
Sample and setting. This multicenter study included 63 patients with a schizophrenia spectrum disorder and 55 healthy comparisons, matched for gender, age, and socioeconomic status (expressed as the highest educational level of one of the parents). Patients were recruited at the University Medical Center Utrecht (The Netherlands) (n = 26) and regional mental health care institutes (Altrecht, GGZ Duin-en Bollenstreek, and GGZ Friesland) (n = 37). Participants were enrolled in the study between May 2007 and May 2010, written informed consent was obtained after the procedures, and possible adverse effects were explained. This trial was part of the TOPFIT project (The Outcome of Psychosis and Fitness Therapy) and registered in the ISRCTN register (http://www.controlled-trials.com/ISRCTN46241817/). After baseline measurements, a computer-generated randomization procedure incorporating concealed allocation (ratio, 1:1), was performed with stratification for gender, recruitment site, and body mass index (BMI, below or above 25). Patients were assigned to exercise or occupational therapy, whereas controls were assigned to exercise or life as usual for 6 months. In specific, schizophrenia spectrum disorder patients had the following diagnoses: schizophrenia (n = 45), schizoaffective (n = 15), or schizophreniform disorder (n = 3) according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) (2). Diagnosis was confirmed by a psychiatrist (WC, NV, or JS) using the Comprehensive Assessment of Schizophrenia and History (4). Patients were stable on antipsychotic medication, i.e., using the same dosage for at least 4 wk before inclusion. They showed no evidence for significant cardiovascular, neuromuscular, endocrine, or other somatic disorders that prevented safe participation in the study (10) . Patients had no primary diagnosis of alcohol or substance abuse and had an intelligence quotient (IQ) Q70, as measured with the Wechsler Adult Intelligence Scale Short Form (WAIS-III SF) (13) .
Healthy participants (n = 55) were recruited from the local population via advertisements. The inclusion criteria for the healthy controls were no diagnosis of psychiatric disorders according to DSM-IV lifetime, no first-degree relative with a psychotic or depressive disorder, and being physically inactive before inclusion (i.e., undertaking less than 1 h of moderate physical activity weekly). The study was approved by the Human Ethics Committee of the University Medical Center Utrecht and research committees of participating centers.
Assessments. CRF was assessed with a cardiopulmonary exercise test (CPET), performed using a 20-WImin j1 stepwise incremental protocol to exhaustion on an upright cycle ergometer (Lode Excalibur; Lode BV, Groningen, The Netherlands). The test was terminated at voluntary exhaustion or conforms criteria as mentioned by the American Thoracic Society/American College of Chest Physicians recommendations (3). CRF, the primary outcome measure, was defined as the highest relative (mLImin j1 Ikg j1 ) mean oxygen uptake at any 30-s interval during the test (V O 2peak ) and the peak work rate at the moment of exhaustion (W peak ) (6) . HR (12-led ECG) and oxygen uptake were measured continuously during the CPET (MetaLyzer 3B; Cortex Medical GmbH, Leipzig, Germany). Before each individual test, ergometer equipment was calibrated according to the manufacturer's instructions. Blood pressure was monitored in a lying down position before commencement of CPET and on the bike just before cessation of the test. Maximal efforts at exhaustion were assumed when the peak RER (RER peak , V CO 2 /V O 2 ) equaled or exceeded 1.1 (17) .
The following exercise parameters were reported, in accordance to the American Thoracic Society/American College of Chest Physicians (3): resting HR (HR rest , in bpm), peak exercise HR (HR peak , in bpm), peak systolic and diastolic blood pressure (mm Hg), relative peak oxygen uptake level ( Cooper and Storer (14) were used.
Intervention. The exercise intervention was designed to improve CRF and primarily incorporated cardiovascular exercises. Muscle strength exercises (six exercises weekly; three times 10 to 15 repetitions maximum for biceps, triceps, abdominal, quadriceps, pectoral, and deltoid muscles) were included to provide variation. The program followed the recommendations of the American College of Sports Medicine (ACSM) (1, 28) . Exercise therapy was supervised by a psychomotor therapist. Information on amount of training and compliance was registered in a logbook. Exercise subjects were prescribed an hour of exercise twice weekly for 6 months. To prevent dropout of subjects due to injury and exhaustion, exercise intensity was increased stepwise (week 1-3, 45%; week 4-12, 65%; week 13-26, 75% of HR reserve based on baseline CPET data (1).
Patients not randomized to exercise therapy were offered occupational therapy 1 h twice weekly for 6 months. Occupational therapy comprised creative and recreational activities. Compared with exercise therapy, occupational therapy provided a similar amount of structure and attention, but no physical activation. Controls not randomized to exercise were assigned to life as usual and were not allowed to incorporate in moderate physical activity more than 1 h weekly.
Statistical analyses. SPSS 18.0.1 (SPSS, Chicago, IL) was used to analyze the data. All statistical tests were performed two tailed, and a P value of G0.05 was considered significant. Data were examined for outliers. All analyses were performed with and without extreme outliers to examine their influence on results. If of nonnormal distribution, logarithmic transformation was applied or nonparametric testing was performed.
Baseline comparisons. Multiple ANOVAs for noncategorical variables and W 2 analyses for categorical variables were used to examine differences between groups in demographics and clinical characteristics. Univariate analyses were used to examine baseline differences in HR rest , HR peak , HR peak , systolic and diastolic blood pressure, relative and absolute V O 2peak , V Epeak , W peak , RER peak , O 2pulse , VAT as well as HR diff between patients and controls and between exercise and occupational therapy/life as usual. Pearson product-moment correlations were calculated to examine the relation between age, BMI, and V O 2peak in both patients and controls. In patients, correlations were calculated as well between V O 2peak and illness duration, severity of psychosis, and antipsychotic medication used (in haloperidol equivalent). Pearson product-moment correlations were also calculated to examine the relation between smoking (average number of cigarettes per day) and percentage of reference relative and absolute CRF.
Comparison with reference data. Paired sample ttests were performed to assess differences in individual baseline and reference relative and absolute V O 2peak , HR peak , O 2pulse , and VAT within subjects, stratified for gender and group (patients vs. controls). Also, differences between reference values and CRF results of patients and controls were calculated and expressed in percentages such that the reference value equaled 100%.
Effects of exercise therapy. For CRF change analyses, minimal compliance was set at 50% of 52 sessions because a minimum workload is needed to be able to expect an effect in untrained subjects (1) . To assess time-by-time effects for CRF parameters, repeated-measures ANOVAs were performed with HR rest , HR peak , peak systolic and diastolic blood pressure, relative and absolute V O 2peak , V Epeak , W peak , RER peak , O 2pulse , VAT, and HR diff as dependent variables and group (patient or control) and randomization (exercise or occupational therapy/life as usual) as independent variables. For relative and absolute V O 2peak analyses, baseline V O 2peak was added as a possible confounder.
RESULTS
Baseline characteristics. Patients were randomized to exercise (n = 31) or occupational therapy (n = 32), whereas controls were randomized to exercise (n = 27) or life as usual (n = 28). As shown in T1 Table 1 , controls were matched to patients for gender, age, and socioeconomic status (40) , but as expected, controls had lower BMI (P = 0.01) and higher IQ (P e 0.001). Furthermore, on average, patients smoked significantly more cigarettes per day than controls (P G 0.001).
Dropout of patients was significantly higher in occupational therapy (n = 7) compared with exercise therapy patients (n = 2, W 2 (2) = 8.33, P = 0.02). One healthy control (randomized to life as usual) dropped out because of serious physical illness. Although at that time undiscovered, this physical illness was present before inclusion and was unrelated to the study. It was the only (serious) adverse event to take place during this trial. Baseline CPET was performed in all included patients and controls. In one patient, no oxygen measurements were acquired because of anxiety.
Thirty-nine patients (62%; exercise, n = 20; occupational therapy, n = 19) and 53 controls (96%; exercise, n = 26; life as usual, n = 27) met minimal compliance demands of 50% of 52 offered sessions. Mean number of sessions in the final group was not statistically different between exercise (41 T 8) and occupational therapy patients (42 T 7, F(1,38) = 1.00, P = 0.32). However, compliance in the final patient group was, albeit at trend-level significance, different from exercise controls (45 T 7, F(1,63) = 2.95, P = 0.09). There were no significant differences between exercise and occupational therapy patients in clinical variables or dose and type of antipsychotic or comedication ( T2 Table 2 ). Baseline comparisons. At baseline, patients had higher HR rest (P G 0.01) and lower HR peak (P G 0.001), peak systolic blood pressure (P = 0.02), relative V O 2peak (P G 0.01), W peak (P G 0.001), RER peak (P G 0.001), V Epeak (P = 0.02), HR diff (P G 0.001), and, at trend-level significance, lower absolute V O 2peak (P = 0.09) than controls. No significant baseline differences between patients and controls in peak diastolic blood pressure (P = 0.68), O 2pulse (P = 0.76), and VAT (P = 0.20) were found between patients and controls ( T3 Table 3 ). Except higher HR rest in exercise therapy (78.3 T 16.3) compared with occupational therapy patients (69.5 T 12.5, F(1,62) = 5.86, P = 0.02), no baseline differences in fitness scores were found between exercise versus occupational therapy patients or exercise versus life-as-usual controls. Relative V O 2peak was not different in compliant (Q50%) versus noncompliant (G50%) patients (P = 0.65) and controls (P = 0.86). Age was inversely correlated to relative V O 2peak in male (r = j0.34, P = 0.01) but not in female (r = j0.39, P = 0.13) patients with schizophrenia and in male (r = j0.27, P = 0.12) and female (r = j0.20, P = 0.42) controls. BMI was inversely correlated to relative V O 2peak in male (r = j0.67, P G 0.001) and female (r = j0.54, P = 0.03) patients with schizophrenia and in male (r = j0.61, P G 0.001) and, at trend-level significance, in female (r = j0.42, P = 0.08) controls. There was a trend-level significant negative correlation between V O 2peak and severity of psychosis in male patients (r = j0.252, P = 0.091) but not in female patients (r = j0.234, P = 0.383). Both in male and female patients, illness duration (males, r = j0.229, P = 0.125; females, r = j0.181, P = 0.503) or antipsychotic medication use (males, r = j0.173, P = 0.263; females, r = j0.201, P = 0.473) was not significantly correlated with V O 2peak . Smoking was inversely correlated to the percentage of reference relative (r = j0.21, P = 0.02) and absolute (r = j0.24,
Comparison with reference data. Individual baseline relative and absolute V O 2peak values for male and female patients and controls are set out against reference values in T4   Table 4 . Relative V O 2peak was 90.5% T 19.7% (P G 0.01) of predicted relative V O 2peak in male patients with schizophrenia compared with 99.6% T 13.5% (P = 0.46) http://www.acsm-msse.org in male controls. In female patients with schizophrenia, relative V O 2peak was 95.9% T 14.9% (P = 0.18) of predicted relative V O 2peak versus 110.3% T 19.0% (P = 0.06) in female control subjects. Absolute V O 2peak in male patients with schizophrenia was 95.5% T 20.7% (P = 0.12) of predicted absolute V O 2peak compared with 103.4% T 13.3% (P = 0.17) in male controls. In female patients with schizophrenia, absolute V O 2peak was 96.8% T 15.3% (P = 0.42) of predicted values compared with 112.3% T 17.0% (P G 0.01) in female controls.
CRF change. Six patients (exercise, n = 3; occupational therapy, n = 3) did not meet the maximal effort criterion (RER peak Q 1.1) and were therefore excluded from the peak exercise data analyses. In one patient (occupational therapy, n = 1), because of anxiety, no breath analyses were assessed. For most subjects, peripheral muscle fatigue (950%) was the main reason for cessation of the test. Other reasons for cessation mentioned were dyspnea (T10%) and general fatigue (G10%).
In patients, exercise therapy increased relative V O 2peak , whereas relative V O 2peak decreased after occupational therapy. In controls, increased relative V O 2peak was seen after exercise therapy and, although to a lesser extent, after life as usual (group, P G 0.01; randomization, P = 0.03). Exercise therapy increased W peak in patients and controls compared with decreased W peak in occupational therapy patients and life-as-usual controls (randomization, P G 0.001). The change over time in W peak differed, at trend-level significance, between patients and controls (group Â randomization, P = 0.09). Increased absolute V O 2peak levels were seen in controls compared with patients (group, P = 0.03). Also, absolute V O 2peak increased, at trend-level significance, after exercise therapy (randomization, P = 0.07). After exclusion of one outlier, the exercise effect was no longer significant (randomization, P = 0.11). Increases in absolute V O 2peak did not differ between groups (group Â randomization, P = 0.95). Reduced O 2pulse was seen in patients compared with controls (group, P = 0.03). A trend-level significant exercise effect was seen for O 2pulse (randomization, P = 0.08). Effects in O 2pulse did not differ between groups (group Â randomization, P = 0.90). VAT increased significantly after exercise subjects compared with nonexercise subjects (randomization, P G 0.01). VAT effects did not differ between groups (group Â randomization, P = 0.37). 
CARDIORESPIRATORY FITNESS IN SCHIZOPHRENIA
No other group, randomization, or group Â randomization effects were seen ( T5 Table 5 ). Except for absolute V O 2peak , exclusion of outliers had no influence on results.
DISCUSSION
The current study examined CRF of patients with schizophrenia as well as matched controls. Furthermore, the effect of a 6-month biweekly exercise therapy on CRF was studied. Male and female patients with schizophrenia had a relative V O 2peak of 34.3 T 9.9 and 24.0 T 4.5 mLIkg
, respectively. Our results demonstrate that patients with schizophrenia, on average, age 29 yr old, have reduced relative V O 2peak and peak workload (W peak ) compared with matched and physically inactive healthy controls. In addition, comparison of individual and reference values for relative V O 2peak shows 10%-15% reductions in CRF levels, especially in male patients with schizophrenia. In our study, the difference in relative V O 2peak between patients and matched controls (4.3 mLIkg ) corresponds to a more than 13% increased mortality risk in patients with schizophrenia (26, 34) .
This randomized clinical trial is the first to examine the influence of exercise therapy on CRF in patients with schizophrenia. Moreover, CRF was assessed by ''the gold standard'' graded exercise test with respiratory gas exchange analysis. Results show exercise, once to twice a week for 6 months, slightly increased relative V O 2peak and markedly improved W peak in patients with schizophrenia compared with decreased relative V O 2peak and W peak in nonexercising patients with schizophrenia. Exercise therapy completely ameliorated this progressive CRF decrease seen in nonexercising patients with schizophrenia. In controls, exercise improved relative V O 2peak by, on average, 2.2 mLIkg j1 Imin j1 and W peak by 9.6 W, indicating that the intervention was effective in increasing CRF in healthy subjects.
Before 2011, only one cross-sectional study investigated CRF through graded exercise testing in patients with schizophrenia. Deimel and Lohmann (16) concluded that patients with schizophrenia demonstrate lower aerobicanaerobic threshold but terminated the test at submaximal workloads, indicating that maximal ergometer testing is unreliable in these subjects. In the past year, four crosssectional studies were published examining CRF in schizophrenia. Two of which incorporated submaximal exercise testing (19, 38) and two ''gold standard'' cardiopulmonary exercise testing (21, 37) . Opposite to Deimel and Lohmann (16) , recent studies show CRF can be reliably assessed in patients with schizophrenia, which is congruent with data from our study (21, 37) . At baseline, all controls and all but four patients with schizophrenia met maximal effort demand (RER peak Q 1.1), although patients with schizophrenia did reach significantly lower average RER peak values than controls. This could in part be due to poorer CRF and the fact that they are not accustomed to perform high-intensity exercise. In accordance with previous CPET studies, our results show decreased relative V O 2peak values in patients with schizophrenia compared with age, gender, and socioeconomic status matched controls (Tables 3 and 4 Imin j1 ) patients. Given higher average age (males 5.4 yr and females 2.6 yr older) with comparable HR peak , this is opposite to expectation. Possibly, the fact that somewhat lower V O 2peak values are achieved in cycle ergometer protocols (present study) compared with treadmill protocols (21) could explain these differences (23) . Another explanation might be that people from Nordic countries have higher fitness levels (7) .
As in our study, Strassnig et al. (37) incorporated cycle ergometer tests. Yet, their participants had extremely low relative V O 2peak values compared with the present study. This is, at least in part, explained by a higher average age (45 vs. 29 yr old) and BMI (37 vs. 26) compared with the present study. In our data, as in Strassnig et al. (37) , age was inversely correlated to V O 2peak . The study by Strassnig et al. (37) provides relevant information on increased cardiovascular risk of obese patients with schizophrenia and possibly describes a later stage of the illness. Given more heterogenic patient characteristics, generalizability of results obtained in this study appears to be better.
Our results demonstrate that exercise, only once to twice a week for 6 months, increased relative V O 2peak and W peak in patients with schizophrenia and inactive controls compared with nonexercising patients and controls. Moreover, contrary to nonexercising controls, relative V O 2peak and W peak reduced in nonexercising patients. The improvement in V O 2peak in exercising controls was larger than that in exercising patients. The difference in relative V O 2peak improvement may in part be due to higher exercise compliance in controls compared with patients. In addition, there is evidence that patients with schizophrenia experience mitochondrial dysfunction, which may also affect their ability to improve V O 2peak (39) . However, Heggelund et al. (22) , although not using a randomized controlled trial, showed that high intensity training (4 Â 4-min bouts at 85%-95% of HR peak ) did increase relative V O 2peak by 12% in patients with schizophrenia. Possibly, relative V O 2peak improvement in exercising subjects (patients and controls) could have been more pronounced if training intensity had been higher than 75% of HR reserve.
Our study is the first to show in a robust experimental randomized controlled design that V O 2peak and W peak , both CRF measures, decreased progressively in nonexercising patients with schizophrenia. In addition, age was inversely associated with relative V O 2peak , more so than that in controls. Research has unequivocally shown decreased V O 2 is associated to increased mortality in healthy males and females (5, 26) . Evidence is growing that poor CRF is a key risk factor for the development of CHD in patients with schizophrenia also (16, 19, 21, 37, 38, 42) . Importantly, our results indicate that, with only 1 to 2 h of exercise therapy per week, this progressive decrease of CRF can be prevented, which should lead to reduced mortality in schizophrenia. We therefore recommend including exercise therapy in the usual care of patients with schizophrenia.
There are some limitations to this study. First, because of dropout and noncompliance, the longitudinal analyses were performed on a relatively small number of patients. Nevertheless, the compliance rate of this study is comparable with previously published exercise trials in patients with schizophrenia and seems a normal feature in patients with schizophrenia (9, 29, 32, 43) . Moreover, long-term exercise adherence rates average 40% to 65% in healthy populations as well (24) . Still, especially in this patient group, therapy adherence is problematic and should be improved. A recent study demonstrated increased adherence to exercise regiments in schizophrenia by incorporation of motivational techniques (8) . Second, higher exercise frequency, longer session duration, and possibly individualized exercise intensity may have improved patients' CRF further. For improvement of CRF in healthy subjects, the ACSM suggests at least three exercise sessions a week (1) . It is noteworthy that our trial shows that only one to two exercise sessions of moderate intensity lead to improved CRF. Third, because no followup period was assessed after study cessation, it is not known whether CRF improvements sustained, nor whether patients have continued exercise regularly.
In conclusion, patients with schizophrenia had lower CRF levels compared with inactive matched controls. Exercise therapy, 1 to 2 h a week for 6 months, was able to increase relative V O 2peak and W peak in exercising patients and controls compared with nonexercising participants. Furthermore, in nonexercising patients, CRF decreased over the 6-month study period. Future studies should enroll more patients and use longer follow-up periods to validate our findings. Priority should be given to exercise adherence improvement in patients with schizophrenia, for example, by incorporating motivational techniques. Increased exercise frequency, session duration, and individualized exercise intensity could lead to more pronounced CRF benefits in patients with schizophrenia (18, 22) .
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